LEXX vs. CUE, HOWL, ADVM, PDSB, ANVS, ANL, GANX, NRXP, ATRA, and KRON
Should you be buying Lexaria Bioscience stock or one of its competitors? The main competitors of Lexaria Bioscience include Cue Biopharma (CUE), Werewolf Therapeutics (HOWL), Adverum Biotechnologies (ADVM), PDS Biotechnology (PDSB), Annovis Bio (ANVS), Adlai Nortye (ANL), Gain Therapeutics (GANX), NRx Pharmaceuticals (NRXP), Atara Biotherapeutics (ATRA), and Kronos Bio (KRON). These companies are all part of the "pharmaceutical products" industry.
Lexaria Bioscience vs. Its Competitors
Cue Biopharma (NASDAQ:CUE) and Lexaria Bioscience (NASDAQ:LEXX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, risk, valuation, profitability, media sentiment, institutional ownership and dividends.
Cue Biopharma has a beta of 1.43, meaning that its stock price is 43% more volatile than the S&P 500. Comparatively, Lexaria Bioscience has a beta of 0.79, meaning that its stock price is 21% less volatile than the S&P 500.
35.0% of Cue Biopharma shares are owned by institutional investors. Comparatively, 13.1% of Lexaria Bioscience shares are owned by institutional investors. 12.3% of Cue Biopharma shares are owned by company insiders. Comparatively, 26.4% of Lexaria Bioscience shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
In the previous week, Lexaria Bioscience had 1 more articles in the media than Cue Biopharma. MarketBeat recorded 3 mentions for Lexaria Bioscience and 2 mentions for Cue Biopharma. Cue Biopharma's average media sentiment score of 1.89 beat Lexaria Bioscience's score of -0.28 indicating that Cue Biopharma is being referred to more favorably in the media.
Cue Biopharma has a net margin of -507.87% compared to Lexaria Bioscience's net margin of -1,849.19%. Lexaria Bioscience's return on equity of -143.50% beat Cue Biopharma's return on equity.
Cue Biopharma currently has a consensus price target of $3.00, indicating a potential upside of 250.47%. Lexaria Bioscience has a consensus price target of $5.00, indicating a potential upside of 474.71%. Given Lexaria Bioscience's higher probable upside, analysts plainly believe Lexaria Bioscience is more favorable than Cue Biopharma.
Lexaria Bioscience has lower revenue, but higher earnings than Cue Biopharma. Lexaria Bioscience is trading at a lower price-to-earnings ratio than Cue Biopharma, indicating that it is currently the more affordable of the two stocks.
Summary
Cue Biopharma beats Lexaria Bioscience on 8 of the 15 factors compared between the two stocks.
Get Lexaria Bioscience News Delivered to You Automatically
Sign up to receive the latest news and ratings for LEXX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding LEXX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Lexaria Bioscience Competitors List
Related Companies and Tools
This page (NASDAQ:LEXX) was last updated on 7/16/2025 by MarketBeat.com Staff
